RxDoctor Payments Data

Ling Li, MD

Neurology · Springfield, MONPI 1235207028

Payments from drug & device makers

$3,163in general payments, 2019–2025

Across 51 payments — averaging $62.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Supernus Pharmaceuticals, Inc.$255
  • Neurocrine Biosciences, Inc.$134
  • Argenx US, Inc.$103
  • AstraZeneca$98
  • Biogen$98
  • plus $236 from 5 others

What the payments were for

  • Travel & lodging$1,83558%
  • Food & beverage$1,32842%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,163 in reported general payments places this provider in the 60th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri

Medicare billing

Part B allowed, 2024
$306,773
Medicare patients
521
Services billed
32,798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine16$189,717
IngrezzaValbenazine Tosylate15$126,909
Aimovig AutoinjectorErenumab-Aooe119$109,901
QuliptaAtogepant33$39,633
Emgality PenGalcanezumab-Gnlm30$27,529
Nurtec OdtRimegepant Sulfate18$21,361
Lacosamide144$21,273
Ajovy AutoinjectorFremanezumab-Vfrm13$19,644
Topiramate ErTopiramate25$18,720
Oxtellar XrOxcarbazepine15$13,545
Levetiracetam346$8,703
Emgality SyringeGalcanezumab-Gnlm12$8,701
Carbidopa-LevodopaCarbidopa/Levodopa496$7,520
Divalproex Sodium83$6,826
Pyridostigmine Bromide76$6,794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$134$126,90915 claims
AbbVieQulipta$17$39,63333 claims
PfizerNurtec Odt, Dilantin$18$26,23540 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$255$13,54515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 381 neurology providers in Missouri.

Other neurology in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →